Phase, Oncology trainee

Phase1 is Orion’s paid trainee programme designed for university students, bringing together a large and diverse group of talents from various fields every year. In addition to interesting summer jobs with meaningful projects, the programme offers a variety of events, networking opportunities with other Phase1 Trainees and Orion employees, as well as small group mentoring to support your career! Could this be the first research phase of your Orion career?

You can find more information about the Phase1 trainee programme on Orion’s website .

The Antibody-Drug Conjugates Team (ADC, one position), Immuno-Oncology Team (IO, one position), and Cancer Genomics Team (CG, one position) are seeking highly motivated students with a strong background in cell biology to join us as Phase1 R&D Trainees during summer 2026 (3–4 months).
You will contribute to early-stage drug discovery in a team focused on target identification, validation, and mechanism-of-action studies. Your tasks will include hands‑on laboratory work such as mammalian cell culture and related assays. Participation in daily laboratory maintenance. All work will be supervised by experienced scientists and research assistants. Above mentioned positions are based in our research laboratories in Turku.

At Orion, you'll get a broad insight into the broad activities of Oncology Research. You'll also get responsibility during the summer as we offer you the opportunity to challenge yourself with interesting and varied tasks. During the summer you will also get a comprehensive overview of Orion's processes, activities and learn about different positions within the corporation.

At Orion, your work creates true impact and well‑being for our customers, patients and society  culture of friendliness, respect, mutual appreciation and diversity creates a safe working environment where you can strive for excellence. We offer a wealth of career paths and development opportunities that support the development of innovative solutions and improving the quality of life.

• Have hands‑on laboratory experience, especially in mammalian cell culture.
• Have completed at least 3 years of university studies in health sciences (e.g., cell biology, molecular biology, biochemistry, pharmacology).
• Are highly motivated, detail‑oriented, and possess good communication skills in English.
• Thrive in a collaborative team environment.

Please apply as soon as possible, but no later than February 1st, 2026. We might start interviewing candidates during the application time, so please ensure that we have your application as soon as possible!

Our Phase1 trainees will be paid a monthly salary of €2370–2625, depending on the number of completed study credits. In addition, the Phase1 trainees are eligible to various employee benefits offered by the company.

If you would like to know more about the application process and timelines, please visit our website .
Welcome to build well‑being with us next summer 2026!

We will carry out a security clearance prior to the employment for the selected person.

Orion’s pharmaceutical innovations are created within its R&D organization. We employ around 400 top professionals in the field of drug discovery and development. We work globally: in Espoo and Turku in Finland, in Nottingham in England and in New York, NY, USA. Orion R&D and the Innovative Medicines business division are dedicated to making a transformation to become a global player in the pain and oncology therapy areas.

Antibody-Drug Conjugates is one of three research teams in Orion’s Oncology R&D. ADCs are targeted biopharmaceutical therapies for cancer treatment. The ADC team drives novel drug discovery projects and identifies/validates potential ADC targets using state‑of‑the‑art technologies. Bonus opportunity:
The ADC team is also looking for a candidate interested in continuing after Phase1 as a Master’s thesis student starting in fall 2026.

Immuno‑Oncology, another key research team in Oncology R&D. The IO team focuses on unmet medical needs, discovering and experimentally validating new IO drug targets with cutting‑edge technologies.

The Cancer…